The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Clinical guidelines currently recommend LABA/LAMA therapy as an alternative to LABA/ICS but evidence on the comparative effectiveness of these combination therapies for COPD is limited. Treatment with ...

Patients with chronic obstructive pulmonary disease (COPD) have multiple breathing problems and, at the more severe stages, experience acute exacerbations of COPD up to three times annually. Because ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. According to a new study published in the Annals of ...

Triple therapy in COPD significantly improves lung function vs LAMA monotherapy, LABA/LAMA, and ICS/LABA, although evidence showing this is often low quality. Triple therapy is likely effective, safe, ...

LAMAs were found to be safe and effective in the treatment of COPD and have been recommended by international clinical guidelines for the management of symptoms in COPD. A population-based cohort ...

Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic ...

Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

April 14, 2020--Clinicians grappling with the pharmacologic management of COPD in patients complaining of exercise intolerance or dyspnea now have new guidance. The American Thoracic Society has ...